From global science to local impact

Saudi Arabia is past the stage of asking how to attract biotech. The opportunity already exists. Global science is abundant, and commercially viable platforms are visible. The real question now is execution — how quickly and decisively these opportunities are scaled locally.

Too often, localization is framed as an incentive discussion rather than a strategic default. When a biotech opportunity is investable and aligned with national priorities, local expansion should be assumed, not negotiated. The focus should be on building capacity, not selling ambition.

This is where fund managers play their true role. They are not marketers of ecosystems. They are executors of capital. Their mandate is to identify quality science, underwrite risk, invest with discipline, and localize businesses that are ready to scale. 

Localization, the real role of fund managers, and why fund-of-funds must enable execution

For this model to work, fund-of-funds structures must enable execution, not attraction narratives. Their role is to back fund managers with the expertise to source and localize real opportunities, not to slow momentum through excessive process or risk aversion.

Biotech localization is capital intensive by design. Facilities, talent development and regulatory readiness require long-term commitment. When capital structures recognize this reality, ecosystems scale. When they do not, opportunity stalls.

Localization is market expansion. It increases revenue, boosts valuations, de-risks investments, builds new teams, and supports resilience and long-term business growth.

From global science to local impact, execution is the difference. And execution only happens when fund managers are empowered to do the job they were hired to do.

• Dr. Huda Alfardus is a businesswoman and biotech investment expert focused on innovation, venture capital, and expanding women’s participation in business and investment markets.